A Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics/Pharmacodynamics of Single and Multiple Dose of HRS-5965 Tablets in Healthy Subjects, and the Food Effect on Pharmacokinetics, and Pharmacokinetics in Subjects With Impaired Renal Function
Latest Information Update: 25 Oct 2024
At a glance
- Drugs HRS-5965 (Primary)
- Indications Glomerulonephritis; Renal failure
- Focus Adverse reactions; First in man
- Sponsors Chengdu Suncadia Medicine
Most Recent Events
- 03 Oct 2024 Status changed from recruiting to completed.
- 13 Oct 2022 Status changed from not yet recruiting to recruiting.
- 24 Aug 2022 New trial record